The last few months have been challenging for all, including labs at the forefront of sight-saving vision research. Many research labs where work was shut down or slowed in March to reduce…

With the revolutionary gene therapy Luxturna being reviewed by Canada’s health agencies this summer, the year 2020 marks a crucial moment in the history of inherited retinal diseases (IRDs), which until now…

Introduction My name is Marlene Cust. I am a senior citizen, and legally blind due to retinitis pigmentosa (RP) and age-related macular degeneration (AMD). In my writing, I want to acknowledge both…

It’s difficult to imagine life without your digital screens, especially at a time when we continue to practice physical distancing to stop the spread of COVID-19. However, with an estimated 1.5 million…

Age-related macular degeneration (AMD) is the leading cause of vision loss in people over the age of 50, affecting approximately 1.4 million Canadians. There are two kinds of AMD: dry AMD which…

Valproic acid (VA), belongs to a family of drugs called HDAC inhibitors (HDACi) and has been tested as a potential treatment for retinitis pigmentosa (RP) with mixed results. In some clinical trials,…